Blackstone, Lion Capital partner to bid for two GSK soft drink brands
The two brands were put up for sale by the UK-based drug manufacturer, as they did not fit GSK’s portfolio. The sale also comes at a time when
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The collaboration will leverage Immunocore’s ImmTAC technology directed towards the cancerous cells avoiding damage to healthy cells and the intracellular changes that occur during cancer or viral infection
Janssen Immunology Therapeutic scientists and The Icahn School of Medicine researchers will jointly work to investigate disease triggers, identify new opportunities for therapeutic interventions and create diagnostics to